An estimated 600 million people worldwide live with hearing loss, a figure projected to affect one in four individuals by 2050 amid global population aging. To combat this widespread auditory decline, Célia Belline founded the start-up Cilcare in Montpellier, France, in 2014, establishing a specialized research platform aimed at restoring function to dormant sensory cells in the inner ear.
From Pharmaceutical Research to Auditory Entrepreneurship
Before launching Cilcare, Belline spent years at Sanofi directing projects focused on population aging. Her research into auditory degeneration began around 2010. When Sanofi ultimately decided to wind down its internal hearing projects to shift corporate focus elsewhere, Belline and fellow Sanofi executives Marie-Pierre Pasdelou and Sylvie Pucheu attempted to sustain the initiative internally for a year before deciding to spin it off independently.
Backed by a small group of local investors and personal bank loans, the founders established Cilcare in Montpellier. To bridge the gap between scientific expertise and commercial viability, Belline undertook specialized training in finance and management at ESSEC Business School and the London Business School. The company achieved profitability in its first operational year, a rare milestone for a biotechnology firm operating in a capital-intensive sector.
Clinical Development and Global Expansion
Cilcare currently maintains a pipeline that includes testing two therapeutic drug candidates slated for clinical evaluation extending toward 2031. Beyond internal drug development, the enterprise generates revenue by conducting molecule testing and data collection services for external pharmaceutical laboratories. This specialized testing division uses proprietary methodologies developed in-house.
To support its international operations, Cilcare established a dedicated office in Boston. The firm employs approximately 50 staff members at its Montpellier headquarters, including pharmacologists and two medical doctors. Financial disclosures show the company has raised roughly 40 million euros from institutional investors Sofilaro and Galia Gestion, alongside establishing a strategic research partnership with Japanese pharmaceutical manufacturer Shionogi.
Corporate Culture and Organizational Governance
Belline approaches human resources management at Cilcare with an emphasis on balancing corporate governance with employee autonomy. Rather than imposing rigid administrative controls that she notes can stifle creativity in growing enterprises, she seeks to preserve operational spontaneity among her research teams. The company’s ongoing research initiatives continue to target early interventions for sensory degradation, positioning the Montpellier firm at the intersection of geriatric pharmacology and auditory neuroscience.
